Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
第3相
実施中（募集終了）
NCT04994509
| 対象疾患 | Pre-Exposure Prophylaxis of HIV Infection |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Gilead Sciences |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 5,368 名 |
|---|
| 介入（薬剤） | Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF, F/TDF, Placebo SC LEN |
|---|
| 開始日 | 2021年8月30日 |
|---|
| 完了日 | 2024年5月27日 |
|---|
| 結果公開日 | 2025年6月19日 |
|---|
概要
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW). The primary objective of this study is to evaluate the efficacy of LEN and F/TAF for HIV-1 PrEP in AGYW at risk of HIV-1 infection.
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
Incidence Phase Screening Visit (Day 1) · HIV-1 events per 100 person-years
| Participants Screened for HIV-1 in Incidence Phase | 2.407 HIV-1 events per 100 person-years |
|---|
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened Set
When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks) · HIV-1 events per 100 person-years
| Randomized Blinded Phase: Lenacapavir | 0.000 HIV-1 events per 100 person-years |
|---|
| Randomized Blinded Phase: F/TAF | 2.018 HIV-1 events per 100 person-years |
|---|
| Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis | 2.407 HIV-1 events per 100 person-years |
|---|
| p-value | <0.0001 |
|---|
| Rate Ratio | 0.000 (95% CI 0.000–0.042) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。